ArticleRevista de neurologia2026
Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status.
Article in Revista de neurologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOcular myasthenia gravis (OMG) is an autoimmune disorder characterized by weakness of the extraocular muscles. This study was developed to investigate the relationship between immunotherapy efficacy and OMG generalization as a function of antibody status, and to explore the efficacy of different immunotherapies in preventing OMG generalization.
methodsThis retrospective study included 60 patients admitted to our hospital with initial OMG who were followed for more than two years. Time to generalization was calculated from symptom onset. The proportional hazards assumption was tested using time-dependent covariates, employing Cox regression and Kaplan-Meier analyses to analyze associations for this patient cohort.
resultsAmong the 60 patients (28 converted OMG; 32 pure OMG), the median time to generalization was 52 months (interquartile range (IQR): 16-117). Antibody positivity was an independent risk factor for generalization (hazard ratio (HR) = 3.89, 95% confidence interval [CI]: 1.26-12.01,
conclusionThe time from OMG onset to generalization can be prolonged. While antibody positivity was independently associated with generalization risk in this study cohort, immunotherapy was linked to a time-stable reduction in this risk among antibody-positive patients. These findings provide a preliminary basis for antibody-status-based individualized treatment in OMG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.